Flamel Technologies SA FLML was a big mover last session, as its shares rose nearly 7% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the company since April 9, as the stock is down almost 27%.
In the last 30 days, the company did not witness any estimate revision while the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher can last.
Flamel Technologies currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Other better-ranked stocks in the medical sector include WuXi PharmaTech (Cayman) Inc. WX, IntelliPharmaCeutics International IPCI and Cardiome Pharma Corp. CRME. All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
CARDIOME PHARMA CRME: Get Free Report
FLAMEL TECH FLML: Free Stock Analysis Report
INTELLIPHARMACT IPCI: Free Stock Analysis Report
WUXI PHARMATECH WX: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Market News and Data brought to you by Benzinga APIsIn the last 30 days, the company did not witness any estimate revision while the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher can last.
Flamel Technologies currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Other better-ranked stocks in the medical sector include WuXi PharmaTech (Cayman) Inc. WX, IntelliPharmaCeutics International IPCI and Cardiome Pharma Corp. CRME. All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
CARDIOME PHARMA CRME: Get Free Report
FLAMEL TECH FLML: Free Stock Analysis Report
INTELLIPHARMACT IPCI: Free Stock Analysis Report
WUXI PHARMATECH WX: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
